AKT1 and metabolic dysfunction-associated steatotic liver disease: Pathways including “Metabolic pathways (mmu01100)”, “Insulin signaling pathway (mmu04910)”, “PPAR signaling pathway (mmu03320)”, “Fatty acid degradation (mmu00071)”, “Carbon metabolism (mmu01200)”, “Glutathione metabolism (mmu00480)”, “Fatty acid metabolism (mmu01212)” and “PI3K-Akt signaling pathway (mmu041151)” were mapped (Figure 4), which were thought to be closely associated with the protective effect of PPC in the improvement of NAFLD.